UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000038134
Receipt No. R000043467
Scientific Title A confirmation test of fatigue feeling decreasing effect after exercise loading by test food consumption
Date of disclosure of the study information 2020/10/01
Last modified on 2020/10/09 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A confirmation test of fatigue feeling decreasing effect after exercise loading by test food consumption
Acronym A confirmation test of fatigue feeling decreasing effect after exercise loading by test food consumption
Scientific Title A confirmation test of fatigue feeling decreasing effect after exercise loading by test food consumption
Scientific Title:Acronym A confirmation test of fatigue feeling decreasing effect after exercise loading by test food consumption
Region
Japan

Condition
Condition Healthy adults
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To confirm decreasing effect of fatigue feeling after exercise loading by test food consumption.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 1.Visual Analog Scale questionnaire of fatigue feeling (before exercise load, just after exercise load finished, 30 min after exercise load finished, 60 min after exercise load finished and a day after exercise load finished)
2.Blood biochemical test (CPK)
3.Plasma TGF-beta concentration
Key secondary outcomes 1.Plasma cytokine concentration (IL-6, TNF-alfa)
2.NK-cell activity
3.Blood amino acid concentration (Gln, BCAA, Trp)
4.Blood biochemical test (AST, ALT, LDH, gamma-GTP, BUN, CRE)
5.Borg scale questionnaire (before exercise load, just after exercise load finished)
6.POMS short version (before exercise load, 60 min after exercise load finished)
7.Incidence rate of adverse events and side effects
8.Others (body weight, BMI, blood pressure and systolic blood pressure, diastolic blood pressure and pulse rate)

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Intake 2 packages of test food a day for 8 days. Rest 4 weeks. Intake 2 packages of control food a day for 8 days.
Interventions/Control_2 Intake 2 packages of control food a day for 8 days. Rest 4 weeks. Intake 2 packages of test food a day for 8 days.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria (1) Males and females of Japanese aged 20 to 64 years old.
(2) Subjects who don't have exercise habituation on a daily basis.
(3) Subjects who receive enough explain of the test, who deeply understanding of the test, and who obtain own consent to participate the test.
Key exclusion criteria Subjects who
1)are given continuous treatment by taking medicines.
2)ingest food for specified health use, functional foods, health foods and supplements (rich containing proteins, peptides and/or amino acids) more than 3 days a week.
3)use medicines that possibly have the influence for fatigue feeling more than 3 days a week. Subjects who ingest food for specified health use, functional foods, health foods and/or supplements those possibly have the influence for fatigue feeling more than 3 days a week.
4)are pregnant or lactating, and females who could become pregnant or lactating during test period.
5)have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ) containing history of surgical operations.
6)excessive alcohol intake.
7)smoke
8)have extremely irregular dining habits, and subjects who have midnight work or irregular shift work.
9)have previous medical history of drug and/or food allergy (especially to wheat and/or to soy bean).
10)are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests.
11)donated over 200mL blood and/or blood components within the last one month to the current study.
12)donated over 400mL blood and/or blood components within the last three month to the current study.

And
13)Females who donated over 400mL blood and/or blood components within the last four month to the current study.
14)Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study.
15)Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study.
(16)Others who have been determined ineligible by principal investigator or sub-investigator.


Target sample size 20

Research contact person
Name of lead principal investigator
1st name Hiroyuki
Middle name
Last name Ikemoto
Organization NISSHIN PHARMA INC.
Division name HEALTH CARE RESEARCH CENTER
Zip code 356-8511
Address 5-3-1, Tsurugaoka, Fujimino-city, Saitama 356-8511, Japan
TEL 049-267-3940
Email ikemoto.hiroyuki@nisshin.com

Public contact
Name of contact person
1st name Masanori
Middle name
Last name Numa
Organization CPCC Company Limited
Division name Planning and Sales Department
Zip code 101-0047
Address 4F Sanwauchikanda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN
TEL 03-5297-3112
Homepage URL
Email cpcc-contact@cpcc.co.jp

Sponsor
Institute CPCC Company Limited
Institute
Department

Funding Source
Organization NISSHIN PHARMA INC.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Institutional Review Board of Chiyoda Paramedical Care Clinic
Address 2F Sanwauchikanda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan
Tel 03-5297-5548
Email IRB@cpcc.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2019 Year 09 Month 24 Day
Date of IRB
2019 Year 09 Month 20 Day
Anticipated trial start date
2019 Year 10 Month 01 Day
Last follow-up date
2019 Year 12 Month 04 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 09 Month 27 Day
Last modified on
2020 Year 10 Month 09 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043467